Awaiting development: Guidance and quality standards

Showing 211 to 220 of 280

Guidance and quality standards awaiting development
Title	Type
Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer ID6433	Technology appraisal guidance
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years TS ID 10237	Technology appraisal guidance
Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]	Technology appraisal guidance
Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer with papillary tumours or carcinoma in situ untreated with BCG TSID 12042	Technology appraisal guidance
Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib [TS ID 12095]	Technology appraisal guidance
Seladelpar for previously treated primary biliary cirrhosis ID 6429	Technology appraisal guidance
Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]	Technology appraisal guidance
Semaglutide for treating non-alcoholic steatohepatitis with significant liver fibrosis ID6458	Technology appraisal guidance
Semaglutide for treating type 2 diabetes (ID1450)	Technology appraisal guidance
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older TSID 11995	Technology appraisal guidance